Ranbaxy slumps, Sun Pharma surges on $3.2b acquisition

Shares in Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after Sun Pharmaceutical Industries said it will buy the company in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker.

Ranbaxy shares had surged 32.6 percent in six consecutive sessions of gains till Friday's close.

Sun Pharmaceutical shares rose as much as 4 percent.

Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own. Daiichi Sankyo (4569.T) said in a statement that it will hold a stake of about 9 percent in Sun Pharmaceutical after the deal.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Time for banks to pass on RBI rate cuts to stakeholders of the economy

    Reserve Bank of India’s decision to cut the repo rate by 25 basis points, from 7.75 to 7.50, is a move in the right direction.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Amita Sharma

IITs: Growing needs with growing numbers

In continuance of the government’s commitment to spread the reach ...

Zehra Naqvi

For the love of language

A video doing the rounds in social media these days ...

Dharmendra Khandal

‘Poop’ coffee anyone? If civets suffer, so be it

That a drink which proudly associates itself with animal poop ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture